
Similar Posts

At-home health test maker Thorne explores sale | Reuters News Agency
Business & FinanceDealsHealth 21 July 2023, 6:41 pm 1 minute Reuters exclusively reported that Thorne HealthTech Inc (THRN.O), a provider of at-home health tests and nutritional supplements, is exploring a sale. Market Impact Thorne’s shares ended trading on Friday up 12.9% at $5.95 on the news, giving the company a market value of $320 million….

Kratom faces scrutiny over health risks
Kratom faces scrutiny over health risks – CBS News Watch CBS News Kratom is commonly marketed as a health wonder, but the FDA warns of “serious adverse effects.” It has even been blamed for several deaths. Mark Strassmann reports. Be the first to know Get browser notifications for breaking news, live events, and exclusive reporting….

New COVID variant JN.1 now comprises up to 30% of US cases: CDC
The latest variant of the COVID-19 virus, JN.1, is now responsible for an estimated 15% to 29% of cases in the U.S. as of Dec. 8, according to a posted update from the Centers for Disease Control and Prevention (CDC). JN.1, which is currently the country’s fastest growing variant, is expected to continue to increase…

Woman Sues Dentist Who Performed Too Much Dental Surgery In 1 Visit
MINNEAPOLIS (AP) — A Minnesota woman has sued her dentist after receiving four root canals, eight dental crowns and 20 fillings in a single visit that she says led to her disfigurement. Kathleen Wilson filed the lawsuit last week in Hennepin County District Court, accusing Dr. Kevin Molldrem of Molldrem Family Dentistry in Eden Prairie,…

Covid inquiry: What is it investigating and how does it work?
Image source, Getty Images By Jennifer Clarke BBC News Prime Minister Rishi Sunak robustly defended the Eat Out to Help Out Scheme he implemented as chancellor during the pandemic in his evidence to the Covid inquiry. Earlier, former Prime Minister Boris Johnson admitted he had underestimated the scale and the challenge of coronavirus. The inquiry’s…

Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years
Artur Widak | Nurphoto | Getty Images Shares of Moderna closed more than 13% higher on Tuesday after Oppenheimer upgraded the stock to “outperform,” saying the Covid vaccine maker could market five products by 2026. The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot. The company’s stock…